Feed SLN
SLSilence Therapeutics plc SLN · NASDAQ
$19.75 -0.25% (-$0.05)
Depth
- Market cap
- $935.2M
- Enterprise value
- $863.1M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 1,522.5x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -176.2%
- Gross margin
- 51.0%
- Net margin
- -9,755.6%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.42
- Free float
- 79.7%
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
- What to watch: Revenue fell by 68% a year over the last 3 years.
- What to watch: Analysts expect revenue to fall by 22% this fiscal year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What to watch: It passes only 1 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number